The DOI matches its Crossref record.
Efficacy of amineptine in the prevention of relapse in unipolar depression
Abstract
The clinical properties of amineptine, a mainly dopaminergic antidepressant, were assessed in a double-blind controlled study involving patients fulfilling Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for unipolar depression. The aim was to determine how relapses could be prevented in this frequently recessing disorder. The study was a two-phase, 12-month, multicentre trial of patients suffering from major depression or dysthymia, diagnosed using DSM-III criteria and evaluated on the Montgomery-Asberg Depression Rating Scale and the Mood, Anxiety, Retardation, Danger scale. Phase I was an open-label 3-month period, with the patients being given 200 mg amineptine per day. The second, 9-month period was a placebo-controlled prophylactic phase. A total of 458 patients were initially included in the study. Of the 376 who completed phase I, 303 (66%) were responders; 284 entered the prophylactic study, randomly assigned to two groups. Of the 134 patients in the placebo group who completed phase II, 25 (18.7%) suffered a relapse, compared with nine out of the 136 (6.6%) in the amineptine group. After resolution of an acute episode of major depression or dysthymia, long-term antidepressant therapy with amineptine significantly reduced the relapse rate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite generally effective short-term treatments for acute episodes of major depression, many patients experience relapses (early return of symptoms within the expected duration of a current episode, of perhaps 3–12 months) or later recurrences (new episodes) following initial short-term improvement or remission (Georgotas 1985; Ferreri et al., 1997; Forte et al., 2015).”
From Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials (2016) · cites this paper as Ferreri et al., 1997
Citations
Cites
Still being checked.
Cited by
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“Despite generally effective short-term treatments for acute episodes of major depression, many patients experience relapses (early return of symptoms within the expected duration of a current episode, of perhaps 3–12 months) or later recurrences (new episodes) following initial short-term improvement or remission (Geo…”
BackgroundSuicide Risk in Placebo-Controlled Studies of Major Depression
Storosum, J. G., van Zwieten, B. J., van den Brink, W., Gersons, B. P. R., & Broekmans, A. W. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1271 · Cited by 114
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Clinical importance of long-term antidepressant treatment
Hirschfeld, R. M. A. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.42.s4 · Cited by 89
Methylphenidate augmentation of citalopram in elderly depressed patients.
Lavretsky, H., & Kumar, A. (2001) · The American journal of geriatric psychiatry · doi:10.1097/00019442-200108000-00015 · Cited by 58
Metadata
- Authors
- Ferreri, M., Colonna, L., & Leger, J.-M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- Centre Hospitalier Esquirol de Limoges (FR)
- Corresponding author
- Ferreri, Maurice
- Venue
- International Clinical Psychopharmacology
- Published
- 1997-07
- Volume
- 12
- Pages
- S39
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2095421870
- Cited by
- 10
- References
- 0
- Citations by year
- 2015: 1
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- amineptine, major depressive disorder, relapse prevention, prophylaxis, dysthymia
- MeSH terms
- Adult, Antidepressive Agents, Tricyclic, Depressive Disorder, Dibenzocycloheptenes, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
